Elevance Health, Inc. (NYSE:ELV) Shares Bought by Stephens Inc. AR

Stephens Inc. AR raised its position in Elevance Health, Inc. (NYSE:ELVFree Report) by 2.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,267 shares of the company’s stock after buying an additional 507 shares during the period. Stephens Inc. AR’s holdings in Elevance Health were worth $9,086,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Alaska Permanent Fund Corp purchased a new position in Elevance Health in the 4th quarter worth approximately $31,000. Hexagon Capital Partners LLC lifted its stake in Elevance Health by 63.0% in the 4th quarter. Hexagon Capital Partners LLC now owns 75 shares of the company’s stock worth $35,000 after purchasing an additional 29 shares in the last quarter. ORG Partners LLC purchased a new position in Elevance Health in the 4th quarter worth approximately $40,000. Private Wealth Management Group LLC purchased a new position in Elevance Health in the 4th quarter worth approximately $41,000. Finally, Orion Capital Management LLC purchased a new position in Elevance Health in the 3rd quarter worth approximately $46,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Down 0.4 %

Shares of NYSE ELV opened at $538.97 on Friday. The firm has a market cap of $125.27 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 1.19 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54. Elevance Health, Inc. has a 52-week low of $412.00 and a 52-week high of $550.34. The business’s 50 day moving average is $526.51 and its two-hundred day moving average is $502.70.

Elevance Health (NYSE:ELVGet Free Report) last posted its quarterly earnings results on Thursday, April 18th. The company reported $10.64 EPS for the quarter, topping the consensus estimate of $10.54 by $0.10. The business had revenue of $42.27 billion during the quarter, compared to the consensus estimate of $42.49 billion. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.46 earnings per share. Research analysts predict that Elevance Health, Inc. will post 37.26 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be paid a $1.63 dividend. The ex-dividend date is Monday, June 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. Elevance Health’s dividend payout ratio (DPR) is 24.64%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group raised their target price on shares of Elevance Health from $585.00 to $605.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. JPMorgan Chase & Co. lifted their price target on shares of Elevance Health from $628.00 to $631.00 and gave the company an “overweight” rating in a research report on Thursday, May 30th. Bank of America lifted their price target on shares of Elevance Health from $621.00 to $646.00 and gave the company a “buy” rating in a research report on Tuesday. StockNews.com lowered shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, Mizuho lifted their price target on shares of Elevance Health from $575.00 to $585.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $601.64.

Read Our Latest Report on Elevance Health

Insiders Place Their Bets

In other Elevance Health news, EVP Felicia F. Norwood sold 14,111 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the completion of the transaction, the executive vice president now owns 31,460 shares in the company, valued at $16,791,460.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.35% of the company’s stock.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Featured Articles

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.